Targeting Behavior

In this article, we discuss how medical providers should engage in better communication with patients to improve outcomes.

Recent Content

A new study shows how to overcome drug resistance after exposure to certain targeted cancer therapies known as RAF and MEK inhibitors.

Kidney tumor

This slide show features various images of papillary, clear cell, chromophobe, and tubulocystic renal cell carcinoma.

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.

Low doses of the antidiabetic drug metformin, and a gene inhibitor known as BI2536 may be able to successfully halt the growth of late-stage prostate cancer tumors, according to a new study published in The Journal of Biological Chemistry.

Genetic testing in metastatic non-small cell lung cancer (NSCLC) patients and subsequent molecular biomarker guided therapy is societally cost-effective compared to a chemotherapy treatment approach without molecular testing.

It seems as though we are seeing more news reports lately on the rising cost of cancer drugs—specifically targeted therapy drugs. Some are even going as far as to ask cancer patients and survivors to sign a petition in hopes of lobbying Congress so that government officials can negotiate lower prices with pharmaceutical companies.

Adding an immune therapy to a targeted drug resulted in responses in lymphoma and several solid tumor mouse models, including breast cancer, that were initially non-responsive to the targeted agent alone.

By clicking Accept, you agree to become a member of the UBM Medica Community.